跳至主要内容
临床试验/NCT05616507
NCT05616507Unknown不适用

A Phase II Trial of Oligo-Fucoidan in Radiation Induced Ling Injury

Taipei Medical University WanFang Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年3月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
Number of Participants With Radiation Pneumonitis

研究概览

简要总结

Fucoidan is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans and non-veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.

详细描述

This project will test the effect of Fucoidan to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer. Thousands of veterans develop lung cancer every year, and are treated by radiation therapy. Studies of lung radiation injury in laboratory animals show that with Fucoidan, investigators can significantly reduce the severity of lung fibrosis and heart toxicity.1,2 Fucoidan is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans and non-veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Ages Eligible for Study: 20-90 years old
  • •Men and women undergoing radiation therapy for lung cancer,no matter the radiation therapy is for curing or for palliating.
  • •Karnofsky performance status,KPS > 70
  • •Absolute Neutrophils > 1000/mm^3
  • •Platelets > 75,000/mm^3
  • •Hematocrit > 25%.
  • •Liver and kidney function tests will be within normal range
  • •Baseline blood pressure will be systolic > 110 mmHg sitting

排除标准

  • •Patients who get lung cancer but no need or without the willingness of radiation therapy
  • •Patients who are taking antiHTN drugs
  • •Women of pregnant, lactating, childbearing potential, or with the intention of becoming pregnant
  • •Patients who are presently participating in another clinical study (except for follow-up surveys for study outcomes)
  • •Patients who are judged to be ineligible for study entry by the investigator or subinvestigator

研究组 & 干预措施

Arm B

No Intervention

observation

Arm A

Experimental

It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.

干预措施: fucoidan (Dietary Supplement)

结局指标

主要结局

Number of Participants With Radiation Pneumonitis

时间窗: 6 months

The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE) (Grade 0-5)

次要结局

  • Number of Participants With Radiation Pneumonitis(two year)
  • Number of Participants With Radiation Pneumonitis(one year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验